On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.

The transaction, which remains subject to certain closing conditions and is expected to close later in 2026, supports UCB’s ambition to bring differentiated solutions to people with severe immune-mediated diseases by focusing on areas of high unmet need.

The Wilson Sonsini team that advised Candid on patent matters related to the transaction includes Laurie McNamara, Michael Hostetler, Yingchun Ni, and Lucas Batties.

For more information, please see UCB’s news release.